Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
about
Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumoursPeptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.Feasibility of imaging esophageal cancer with labeled somatostatin analogueHealth-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Carcinoid syndrome: diagnosis and medical management.Riding a roller coaster: narrative typologies of patients with neuroendocrine tumors.Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin AnalogsPatient-reported outcomes in subjects with neuroendocrine tumors of the pancreasPeptide receptor therapies in neuroendocrine tumors.Somatostatin analogs for the treatment of neuroendocrine tumors.Role of everolimus in pancreatic neuroendocrine tumors.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.Lutetium-labelled peptides for therapy of neuroendocrine tumours.Treatment options for unresectable neuroendocrine liver metastases.Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs).Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.Modeling combined radiopharmaceutical therapy: a linear optimization framework.Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.68Ga-DOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid.Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
P2860
Q28071978-E0D9E4CE-BBA0-4DA0-B4CE-D56989B652D1Q33397018-5570F503-23A5-4ECB-B290-78DD26B8B728Q33782024-2585BE5D-5078-4CF0-8333-390038E4B22FQ34157391-027CA56B-B801-4842-89CF-EAD8FE0456CDQ34400151-E3753545-9106-49D7-9EE5-74EB4EC95C1BQ34452319-CFD46FFA-8359-4062-9519-98C5CAD2794BQ35049485-B6CA52C7-7AB2-40A5-88C5-D8F4C26B2BFBQ35738251-900F9595-C28F-443A-B950-0B23ECF1EC60Q35999552-87A05F6B-4FF3-4205-B074-34A074F2FA86Q36008285-9574359E-4DF1-41DB-87B1-6314DCE3B3E9Q36380878-BC4E77B1-A68B-455A-A8AE-1B53410ECCE2Q36395275-9802D552-F8F2-425C-864F-75346164ABB0Q36892294-2FB53A26-5164-493E-AED5-ECC3E37E3EB7Q37164623-21507F22-46F6-4652-9559-0DE9240775B8Q37402462-9A312383-63DE-4FC2-BB65-DE80EF78CAFFQ37563878-8F5C7BAD-32B3-476D-94FC-A22FF1B8910CQ37849210-E7AFCC4B-662F-43F4-B5F1-17AD3180F5A5Q37935772-3ED7AB57-998F-40B2-A29F-8893C66A2E17Q37975101-5892434A-D552-4B57-9F5A-D5694C87CCFDQ37990411-9AEA254C-53FA-412F-8E45-E3499A55FE66Q38014498-DF57F7E9-FB7A-4C50-806C-F5AC411580A9Q38544844-248C2F59-8EA7-4800-AE05-BA09024228E9Q38694105-DEC37346-0563-4D72-AD7F-3D38A64A08F9Q38870046-EB4D6D4D-FB87-4C6F-9A6A-356B97FCF2E2Q39338039-0D54C64D-78DD-465B-9964-612DFC4D6EA3Q39590717-5E9BDE1E-2FDE-4C3A-A9FA-4C7DF86870F5Q41143314-5683C765-7F8D-443C-BD58-0474566B34E9Q46149964-2CFF85D0-CC18-4725-8D45-ED2706B4F766Q47653267-7A60F260-FD20-459D-A949-8C6959F3AE30Q51300108-CE003C23-B26A-4AA2-A711-261D89C6E756Q52982515-615D9516-99AD-4CDB-B435-74328C20C4C0
P2860
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Quality of life in patients wi ...... [177Lu-DOTA0,Tyr3]octreotate.
@en
Quality of life in patients wi ...... [177Lu-DOTA0,Tyr3]octreotate.
@nl
type
label
Quality of life in patients wi ...... [177Lu-DOTA0,Tyr3]octreotate.
@en
Quality of life in patients wi ...... [177Lu-DOTA0,Tyr3]octreotate.
@nl
prefLabel
Quality of life in patients wi ...... [177Lu-DOTA0,Tyr3]octreotate.
@en
Quality of life in patients wi ...... [177Lu-DOTA0,Tyr3]octreotate.
@nl
P2093
P356
P1476
Quality of life in patients wi ...... [177Lu-DOTA0,Tyr3]octreotate.
@en
P2093
Dik J Kwekkeboom
Eric P Krenning
Jaap J M Teunissen
P304
P356
10.1200/JCO.2004.10.016
P407
P577
2004-07-01T00:00:00Z